-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Atezolizumab in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Atezolizumab in Follicular Lymphoma Drug Details: Atezolizumab (Tecentriq) is an antineoplastic agent....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Delgocitinib in Alopecia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Delgocitinib in Alopecia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Delgocitinib in Alopecia Drug Details: Delgocitinib (Corectim) acts as anti-allergic agent. It is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Delgocitinib in Psoriasis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Delgocitinib in Psoriasis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Delgocitinib in Psoriasis Drug Details: Delgocitinib (Corectim) acts as anti-allergic agent. It is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Delgocitinib in Hand Dermatitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Delgocitinib in Hand Dermatitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Delgocitinib in Hand Dermatitis Drug Details: Delgocitinib (Corectim) acts as anti-allergic agent....
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Trabectedin in Ewing Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trabectedin in Ewing Sarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trabectedin in Ewing Sarcoma Drug Details: Trabectedin (Yondelis) is an anti tumor...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Erenumab in Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Erenumab in Pain report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Erenumab in Pain Drug Details: Erenumab (Aimovig, Aerinex, Pasurta, Glaseeq) is a human...
-
Product Insights
Basal Cell Carcinoma (Basal Cell Epithelioma) – Drugs In Development, 2023
Global Markets Direct’s, ‘Basal Cell Carcinoma (Basal Cell Epithelioma) - Drugs In Development, 2023’, provides an overview of the Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Chronic Urticaria Or Hives – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Urticaria Or Hives - Drugs In Development, 2023’, provides an overview of the Chronic Urticaria Or Hives pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Urticaria Or Hives, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Alopecia – Drugs In Development, 2023
Global Markets Direct’s, ‘Alopecia - Drugs In Development, 2023’, provides an overview of the Alopecia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alopecia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Plaque Psoriasis (Psoriasis Vulgaris) – Drugs In Development, 2023
Global Markets Direct’s, ‘Plaque Psoriasis (Psoriasis Vulgaris) - Drugs In Development, 2023’, provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...